2025-11-11 – Press Releases – www.prnewswire.com
MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89Zr-girentuximab) in metastatic triple negative breast…
